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Introduction: The introduction of targeted therapies in non-small cell lung cancer (NSCLC) treatment 
has led to emerging toxicities, whose management and impact on quality-of-life (QoL) is not clearly defined. 
Aim of this Italian multicenter survey was to highlight any discrepancy between patients’ and clinicians’ 
perception of such toxicities in order to improve their management.
Methods: From October 2013 to April 2014, 133 NSCLC advanced patients, treated with targeted 
therapies, were consecutively enrolled to assess toxicities and QoL with dedicated questionnaires. One 
hundred and sixteen patients were included in the final analysis, having attended three consecutive 
evaluations (T0, T1, T2), starting at least 15 days after the biological treatment. The survey required 
monthly compilation of both physicians and patients’ questionnaires, basing adverse event evaluation on 
CTCAE version 4.0. 
Results: Most of the patients received either an EGFR-TKI or an anaplastic lymphoma kinase (ALK) 
inhibitor as targeted therapy (84.5% and 13.8%, respectively). At every checkpoint (T0, T1, T2) a significant 
difference in terms of perception of targeted therapies-related toxicities of any type and grade was described 
(P value =0.0001 in all cases). This difference was more pronounced for skin toxicity, fatigue and diarrhea. 
Furthermore, also the assessment of QoL revealed contrasting data between patients and clinicians, mainly 
QoL reported as good by the majority of patients and daily activities considered as slightly influenced by 
targeted therapies.
Conclusions: In our knowledge, this is the first prospective survey in patients and doctors specifically 
designed for targeted therapies in advanced NSCLC. The results show an underestimation of toxicities 
by clinicians when compared with patients, the difference being greater for adverse events more strongly 
associated with daily life and QoL. Further studies are needed to confirm our first results. The discrepancy 
in perception of targeted therapies-related toxicities should be a result from which to start thinking about a 
new approach in their management.
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Introduction
The knowledge of molecular mechanisms of cancer 
pathogenesis has led to the discovery of pathways directly 
involved in cell transformation. In patients’ subgroups, 
malignancies can result from genetic alterations in a single 
gene. The cancer becomes dependent upon, or “addicted” 
to, signaling from a specific transcribed protein which 
often is a tyrosine kinase receptor. In advanced non-
small cell lung cancer (NSCLC), the epidermal growth 
factor receptor (EGFR) and the anaplastic lymphoma 
kinase (ALK) are proteins for which specific inhibitors are 
currently available in the clinical practice. About 10-15% of 
Caucasians are affected by advanced NSCLC “addicted” to 
activating mutations of EGFR and receive greater benefit 
from first-line EGFR-tyrosine kinase inhibitors (TKIs) such 
as gefitinib, erlotinib and afatinib (1). Erlotinib is currently 
licensed also for unselected pretreated NSCLC patients on 
the basis of survival benefit reported compared with placebo 
in the BR.21 trial (2). In another 2-5% of patients, NSCLC 
is “addicted” to ALK-translocations and crizotinib, an 
ALK-TKI, is currently the standard second-line therapy for 
this subset of patients (3) (at least in Italy). All these TKIs 
are small molecules administered orally daily and are used 
according to the “personalized medicine” model, for which 
every single tumor might potentially benefit from a specific 
individual treatment, reaching unprecedented impressive 
outcomes in NSCLC (1,3). Among the many anti-
angiogenic compounds that have been tested in advanced 
NSCLC, only bevacizumab has been approved in first line 
treatment in association with carboplatin-paclitaxel or 
cisplatin-gemcitabine. To date, no specific target has been 
identified to select the population receiving greater benefits 
from this treatment, as in fact the choice is currently based 
on clinical, radiologic and histological characteristics.
Despite the high selectivity of TKIs and the growing 
amount of data coming from clinical trials, in daily clinical 
practice several previously unknown and sometimes 
unpredictable adverse events are emerging directly related 
with targets also present in normal tissues, and which are 
inhibited or modulated by the specific drug. The main 
organs and systems involved are: the skin and mucous 
membranes, the gastrointestinal tract, the cardiovascular, 
respiratory and neurologic systems (1-3). Nevertheless, 
treating clinicians must be challenged to recognize and 
measure these “new” adverse events and understand how to 
manage them because, even if in the majority of cases they 
are of mild-moderate grade and reversible on treatment 
cessation, they could deeply influence patients’ quality-of-
life (QoL).
Several reports underlined a strong discrepancy between 
patients’ self-assessment and investigators’ evaluation of the 
presence and grade of symptoms related to the treatment (4). 
Based on these considerations, we investigated the toxicity 
profile and their impact on patients’ daily life when treated 
with targeted therapies, measuring the patient point of view 
and comparing this with that of the referring physician. The 
aim was to highlight any discrepancy and evaluate how this 
should be corrected in order to improve management.
Methods
Between October 2013 and April 2014, 133 patients with 
advanced NSCLC (IIIB and IV stages, according to the 
UICC TNM 7th edition), treated with targeted therapies at 
any lines of treatment within seven Oncologic Institutions 
involved in this Italian multicentre survey, were consecutively 
and prospectively enrolled. They were assessed for toxicities 
and impact on QoL with specific monthly questionnaires. 
The questionnaire and the project were designed and 
supported by WALCE Onlus (Women Against Lung 
Cancer in Europe), a European association devoted to lung 
cancer patients and their families in terms of information, 
support and primary prevention (5). Achievement of main 
inclusion criteria required a treatment with an approved 
targeted therapy (allowing also the enrollment of patients 
already included in clinical trials), at least 15 days of therapy 
since the beginning of the biological treatment (T0), patient 
age ≥18 years, a life expectancy ≥6 months (according 
to clinical judgment of the referring physician) and 
adequate verbal comprehension skills for completing the 
questionnaires provided. No limitations as regards type of 
targeted therapy employed, number of cycles previously 
administered and kind of preceding oncologic treatments 
were imposed.
Among the 133 patients recruited, 116 were considered 
suitable for final analysis because they attended at least 
three consecutive monthly evaluations (T0, T1, T2) to 
reach a meaningful outcome. At every checkpoint, patients 
and referring clinicians received a specific questionnaire 
(and relative explanation letter) for the assessment of skin 
toxicity, oral mucositis, fatigue, visual disorders, nausea, 
diarrhea and hypertension potentially related to targeted 
therapies observed during the treatment and the impact 
of these toxicities on QoL. The remaining 17 patients, 
considered not suitable for final evaluation, had disease 
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progression that required a therapeutic shift (14 cases) 
or a worsening of clinical conditions that did not allow 
other oncologic treatments, but only best supportive 
care (3 cases). All patients fulfilled all questionnaires at 
all checkpoints immediately before, while their referring 
clinicians after the scheduled visit. Table 1 summarizes 
the participating centers, main characteristics of the 116 
evaluable patients and targeted therapies.
The survey required completion of both questionnaires 
(physicians and patients), basing adverse event evaluation 
on the CTCAE version 4.0 (6). The points investigated 
were chosen according to the major reported toxicities 
in association with approved targeted drugs in advanced 
NSCLC, and are listed in Table 2.
Statistical analysis of collected qualitative data was 
performed using Fisher’s exact test. Two-tailed P values 
were used, and results were considered significant at P 
values <0.05.
Results (Figures 1-3)
Among the 116 patients included in the final analysis, 98 
(84.5%) were treated with an EGFR-TKI (used prevalently 
alone, but in combination with an antiangiogenetic drug 
in two cases, and with a MET-inhibitor in one case, since 
these three patients were included in controlled clinical 
trials), 16 patients (13.8%) with an ALK inhibitor, 1 patient 
with bevacizumab plus platinum-based chemotherapy and 2 
patients (1.7%) with a single antiangiogenic agent, without 
no addition of biological drugs (Table 1). Median duration 
of treatment was 13.4 months (range, 2.7-76.1 months).
At baseline (T0), among the 232 questionnaires evaluated 
(116 from patients and 116 from clinicians, respectively) a 
statistically significant difference in terms of perception of 
any-type and any-grade targeted therapies-related toxicities 
was described (two tailed P value =0.0001). Only few 
cases of any-type grade 3 and 4 toxicities were described, 
according to the good treatment safety profile. Similar results 
were observed for T1 and T2 (two tailed P value =0.0001 
and 0.0001, respectively).
Relevant data in terms of different perception of 
toxicities between patients and referring clinicians were 
observed at every checkpoint (T0, T1, T2) especially for 
skin toxicity, fatigue and diarrhea (Figure 1A, Figure 2A, 
Figure 3A, respectively). About 75.0%, 77.6% and 73.3% of 
patients, at T0, T1 and T2, respectively, declared to have 
experienced any grade skin toxicity during the preceding 
weeks of treatment, compared to 56.9%, 58.6% and 55.2%, 
respectively, according to clinicians’ evaluation. Two-
tailed Fisher’s exact P value was 0.0054, 0.003 and 0.006, 
respectively. Analysis of skin toxicity grades revealed a lower 
perception of grade 1 toxicitiy by patients, when compared 
to their referring clinicians, and a higher perception of 
grade 2 toxicities (Figure 1B). Similar data were observed 
for fatigue: evaluation of patients’ questionnaires revealed 
69.0%, 64.6% and 61.2% of targeted therapies-related 
fatigue, at T0, T1 and T2, respectively, compared with 
44.0%, 51.7% and 52.6%, respectively, according to 
clinicians’ evaluation. Two-tailed Fisher’s exact P value was 
0.0002, 0.0621 and 0.2327, respectively. Similarly to skin 
Table 1 Characteristics of evaluated patients
Patients N=116 
(100%)
Participating centers, N (%)
Thoracic Oncology Department, San Luigi 
Hospital, Orbassano 
32 (27.6)
Oncology Unit, Valduce Hospital, Como 3 (2.6)
U.O. Medical Oncology, National Cancer 
Research Centre Giovanni Paolo II, Bari
14 (12.1)
Medical Oncology Unit, University Hospital of 
Parma
15 (12.9)
Medical Oncology, San Gerardo Hospital, Monza 35 (30.2)
Medical Oncology, Presidio Ospedaliero E. 
Morelli AOVV, Sondalo
7 (6.0)
Division of Medical Oncology, SG Moscati 
Hospital, Avellino
10 (8.6)
Sex, N (%)
M 59 (50.9)
F 57 (49.1)
Age 65.6 years
Targeted therapy, N (%)
Gefitinib 64 (55.1)
Erlotinib 28 (24.1)
Erlotinib plus bevacizumab erlotinib plus MET 
inhibitor versus placebo
2 (1.7)
Afatinib 1 (0.9)
Crizotinib 3 (2.6)
ALK inhibitor other than crizotinib 15 (12.9)
Bevacizumab 1 (0.9)
Carboplatin/paclitaxel plus bevacizumab 1 (0.9)
Patients enrolled in controlled clinical trials 1 (0.9)
ALK, anaplastic lymphoma kinase. 
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Table 2 Topics investigated and patients questionnaire
Skin toxicity
During the previous days of therapy, did you develop skin 
toxicity of any type? (i.e., dryness, flaking and/or fissuring 
of the skin, erythema, pruritus, acneiform rash, infection or 
nail’s abnormalities) 
-Yes
-No
If Yes, provide the degree of severity
-Grade 0 (absent)
-Grade 1 (mild, without need of treatment)
-Grade 2 (moderate, need of minimum local treatment)
-Grade 3 (severe, need of medical treatment with 
restriction of daily activities)
-Grade 4 (severe, need of urgent medical treatment)
Oral mucositis
During the previous days of therapy, did you develop 
oral mucositis? (feeling burning sensation in the mouth, 
infection of the mouth)
-Yes
-No
If Yes, provide the degree of severity
-Grade 0 (absent) 
-Grade 1 (mild, without need of treatment) 
-Grade 2 (moderate, not interfering with feeding) 
-Grade 3 (severe, with limitation of feeding) 
-Grade 4 (severe, need of urgent medical treatment)
Fatigue
During the previous days of therapy, did you experience 
fatigue?
-Yes
-No
If Yes, provide the degree of severity
-Grade 0 (absent) 
-Grade 1 (mild, without restriction of daily activities) 
-Grade 2 (moderate, partial restriction of daily activities)
-Grade 3 (severe, wide restriction of daily activities)
-Grade 4 (severe, need of urgent medical treatment)
Table 2 (continued)
Table 2 (continued)
Visual disorders
During the previous days of therapy, did you experience 
visual disorders?
-Yes
-No
If Yes, provide the degree of severity
-Grade 0 (absent)
-Grade 1 (mild)
-Grade 2 (moderate, without any limitation of daily 
activities)
-Grade 3 (severe, with limitation of daily activities)
-Grade 4 (severe, need of urgent medical treatment)
Nausea
During the previous days of therapy, did you experience 
nausea?
-Yes
-No
If Yes, provide the degree of severity
-Grade 0 (absent) 
-Grade 1 (mild, loss of appetite without alteration in 
eating habits)
-Grade 2 (moderate, reduction of food intake without 
weight loss)
-Grade 3 (severe, inadequate caloric and/or liquids 
intake)
-Grade 4 (severe, need of urgent medical treatment)
Diarrhea
During the previous days of therapy, did you experience 
diarrhea?
-Yes
-No
If Yes, provide the degree of severity
-Grade 0 (absent) 
-Grade 1 (mild, less than 4 episodes of diarrhea in  
24 hours)
-Grade 2 (moderate, 4-6 episodes of diarrhea in 24 hours)
-Grade 3 (severe, more than 7 episodes of diarrhea in  
24 hours)
-Grade 4 (severe, need of urgent medical treatment)
Table 2 (continued)
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toxicity grades, at every checkpoint (T0, T1, T2) patients’ 
evaluation of fatigue, compared to clinicians’, resulted lower 
for grade 1, higher for grade 2, minimal for grade 3 and 4 
(Figure 2B). Patients’ questionnaires revealed 62.9%, 44.0% 
and 50.9% of targeted therapies-related diarrhea at T0, T1 
and T2, respectively, compared with 45.7%, 34.5% and 
31.9%, respectively, from clinicians’ questionnaires. Two-
tailed Fisher’s exact P value was 0.0121, 0.0079 and 0.0050, 
respectively. Overall, patients’ perception of any-grade 
diarrhea resulted higher when compared with clinicians’ 
evaluation (Figure 3B).
A similar trend was observed for the other four items 
evaluated, summarized in Table 3. For hypertension in 
particular, 18.1%, 13.8% and 11.2% of patients, at T0, T1 
and T2 respectively, did not know their blood pressure value.
Targeted therapies were in general assessed as well 
tolerated by both patients and referring clinicians. The 
assessment of QoL also revealed discordant data, showing 
for patients, when compared with clinicians, a lower 
perception of targeted therapies-related influence on 
daily life when deemed slightly influenced, but a higher 
perception when considered not interfering at all or 
acceptably influenced with daily activities and relationships 
(Figure 4). At T0, QoL was deemed excellent, good, fairly 
good and unsatisfactory by 15.5%, 44.8%, 35.4% and 4.3% 
of patients, respectively, compared with 21.5%, 56.9%, 
19.9% and 1.7% of clinicians (Figure 5). Similar results 
were observed at T1 and T2.
Discussion
The development of a large number of targeted therapies 
Table 2 (continued)
Hypertension
During the previous days of therapy, did you experience 
rising values of blood pressure?
-Yes
-No
-I don’t know
If Yes, provide the degree of severity
-Grade 0 (absent)
-Grade 1 (mild, transient and/or asymptomatic rise of 
blood pressure)
-Grade 2 (moderate, persistent and/or symptomatic rise 
of blood pressure, e.g., headache)
-Grade 3 (moderate, persistent rise of blood pressure 
with need of medical treatment )
-Grade 4 (severe, need of urgent medical treatment)
Influence on daily living
How much do you believe that the ongoing treatment can 
influence your daily activities and relationships?
-Not at all
-A little
-Acceptably
-Not acceptably
Quality of life
How do you rate your present quality of life?
-Excellent
-Good
-Fairly good
-Unsatisfactory
CTCAE version 4.0 was applied for the assessment of 
toxicity grades using a comprehensive language in patients’ 
questionnaires.
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Figure 1 (A) Different perception of skin toxicity; (B) relative 
toxicity grades.
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for NSCLC treatment in the past decade has led to the 
possibility to better personalize the therapeutic options for 
patients with specific clinical characteristics and molecular 
features. However, this has also led to the emerging of 
related toxicities, whose management and impact on QoL 
is frequently challenging. Difficulties in the management of 
such toxicities often come from the accelerated shift from 
clinical trial to clinical practice settings of these new classes 
of drugs, and from the onset of previously unexpected 
adverse events. Despite the fairly positive toxicity profile 
of targeted therapies, some patients are extremely sensitive 
to these drugs and can develop severe toxicities which 
can impact their daily life and influence QoL. Moreover, 
discrepancy between patients’ and clinicians’ perception of 
targeted therapies-related toxicities makes the daily clinical 
effort that these patients require even more difficult.
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Figure 2 (A) Different perception of fatigue; (B) relative toxicity 
grades.
Figure 4 Influence of targeted therapies on daily activities and 
relationships.
Figure 3 (A) Different perception of diarrhea; (B) relative toxicity 
grades.
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Analysis of the results of this Italian multicenter survey 
emphasizes a probably general underestimation of toxicities 
by clinicians when compared to patients’ perception. 
This trend was observed at baseline (T0), but also at 
every subsequent checkpoints (T1, T2), probably due to 
the attitude of clinicians in evaluating the toxicities from 
targeted therapies over time and, simultaneously, to the 
very low cumulative effect of such toxicities according to 
patients’ evaluation.
Discrepancy between patients and clinicians evaluation 
of toxicities seems to be greater for adverse events more 
strongly associated with daily life and QoL, such as skin 
toxicity, fatigue and diarrhea. This was observed for CTCAE 
version 4.0 grade 2 or higher skin toxicity, fatigue, and for 
any-grade diarrhea (Figure 1B, Figure 2B, Figure 3B).
Data regarding influence of targeted therapies on daily 
life strongly reflect literature data of good tolerance for 
long-term biological treatments in NSCLC patients (6-8).
As for Quinten et al. (9), in this survey patients-reported 
scores differed from clinicians-reported scores. In this 
publication, baseline data regarding six cancer symptoms 
(pain, fatigue, vomiting, nausea, diarrhea, and constipation) 
from a total of 2,279 cancer patients from 14 closed EORTC 
randomized controlled trials were analyzed. In each trial, 
selected for retrospective pooled analysis, both clinicians 
and patients’ symptoms scoring were reported. In this study, 
different opinions were reported between patients and 
clinicians, similarly to what we described in our survey, but 
the Authors reported also a prognostic impact on survival. 
Cox models of overall survival that took into account both 
patients and clinicians’ scores gained more predictive 
accuracy than models that took into account clinicians’ scores 
alone for each of four symptoms: fatigue, vomiting, nausea, 
and constipation (9). This stresses the need to have patients’ 
reports together with referring clinicians’ clinical outcomes.
The impact on daily activities and relationships was 
globally assessed as not to interfere at all by a consistent 
number of patients, similarly to the clinicians’ perception, 
underlining the great clinical benefit of this kind of 
treatment, besides the possibility of disease control. On the 
contrary, when impact on daily life was considered slightly 
influenced by targeted therapies, the assessment of patients 
resulted lower in comparison to the referring clinicians, 
probably due to the impact of invalidating toxicities on their 
relationships and activities (Figure 4).
At every checkpoint, most patients reported QoL as 
good (44.8% at T0), although their evaluation was globally 
lower when compared to clinicians’ perception (56.9% at 
the same checkpoint), probably because QoL was strongly 
influenced by symptoms and distress related to the disease 
(Figure 5).
Figure 5 Influence of targeted therapies on quality of life.
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Table 3 Different perception of toxicities from targeted 
therapies between patients and clinicians and related statistical 
significance
Patients’ 
evaluation§ (%)
Clinicians’ 
evaluation§ (%)
P value¶
Oral mucositis
T0 31.9 18.1 0.0225*
T1 37.9 18.1 0.0012*
T2 31.9 22.4 0.1396
Visual disorders
T0 37.1 13.8 0.0001*
T1 37.1 17.2 0.0011*
T2 29.3 19.0 0.0909
Nausea
T0 31.0 16.4 0.0131*
T1 25.0 14.7 0.0693
T2 21.6 12.9 0.1170
Hypertension
T0 8.6 3.4 0.1662
T1 10.3 3.4 0.0668
T2 11.2 6.0 0.2417
§, toxicity rate of any grade during the previous weeks of 
treatment; ¶, two-tailed Fisher’s exact P values; *, statistically 
significant values.
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One weakness of this survey could be related to the fact 
that few patients underwent therapy with bevacizumab and 
this might limit the ability to interpret the data for this 
subgroup, although the percentage is quite consistent with 
the use of this drug in this context in Italy.
One strength is the design of the survey, prospectively 
collecting information specifically in patients with advanced 
NSCLC treated with already approved targeted drugs. 
The poor perception of clinicians of the most invalidating 
toxicities according to patients’ evaluation should be a 
crucial result from which to start thinking about a new 
approach for a better evaluation of the impact of targeted-
therapy-related toxicities on patients’ general conditions, 
relationships and QoL. The questionnaires employed in 
this survey were extremely simple to understand and fill in 
by both patients and clinicians. A few minutes to answer to 
the questions proposed can directly address very important 
aspects for patients’ health and psychological well-being. 
Moreover, a better understanding by clinicians of the 
clinical and psychological distress related to a targeted 
treatment regimen could enhance the relationship between 
patients and his/her referring clinicians, but also improve 
the therapeutic intervention in case of toxicities.
Conclusions
Despite this Italian multicenter survey was the first 
experience in evaluating toxicities of targeted therapies with 
a new specific monthly questionnaire, and the need of a 
larger number of evaluated patients to confirm the collected 
data, the results from this first analysis are promising. 
The questionnaires proposed could be an effective tool 
to understand the approach to a better management of 
targeted-therapy-related toxicities, and to avoid the current 
discrepancy between patients and clinicians perception of 
adverse events and their impact on QoL.
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